Salvetti Chiara, Vitale Candida, Griggio Valentina, Drandi Daniela, Jones Rebecca, Bonello Lisa, Bomben Riccardo, Bragoni Alberto, Bagnara Davide, Fais Franco, Gattei Valter, Cavallo Federica, Zamò Alberto, Coscia Marta
Division of Hematology, University of Torino, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy.
Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
Front Oncol. 2022 Jun 6;12:917115. doi: 10.3389/fonc.2022.917115. eCollection 2022.
Two main variants of Richter syndrome (RS) are recognized, namely, the diffuse large B-cell lymphoma (DLBCL) and the Hodgkin's lymphoma (HL) variant. Clonal relationship, defined as an identity of the immunoglobulin heavy chain variable (IGHV) region sequence between chronic lymphocytic leukemia (CLL) and RS clones, characterizes patients with a poor prognosis. Due to method sensitivity, this categorization is performed without considering the possibility of small-size ancillary clones, sharing the same phenotype with the preexisting predominant CLL clone, but with different IGHV rearrangements. Here we describe and molecularly profile the peculiar case of a patient with a CLL-like monoclonal B-cell lymphocytosis (MBL), who sequentially developed a DLBCL, which occurred concomitantly to progression of MBL to CLL, and a subsequent HL. Based on standard IGHV clonality analysis, DLBCL was considered clonally unrelated to the concomitantly expanded CLL clone and treated as a lymphoma, achieving a persistent response. Three years later, the patient further developed a clonally unrelated HL, refractory to bendamustine, which was successfully treated with brentuximab vedotin and radiotherapy, and later with pembrolizumab. We retrospectively performed additional molecular testing, by applying next-generation sequencing (NGS) of immunoglobulin repertoire (Ig-rep) techniques and a more sensitive allele-specific oligonucleotide-droplet digital PCR (ASO-ddPCR) strategy, in order to quantitatively investigate the presence of the rearranged IGHV genes in tumor specimens collected during the disease course. In this highly complex case, the application of modern and sensitive molecular technologies uncovered that DLBCL, initially considered as a lymphoma, was instead the result of the transformation of a preexisting ancillary B-cell clone, which was already present at the time of first MBL diagnosis. A similar approach was also applied on the HL sample, showing its clonal unrelatedness to the previous MBL and DLBCL.
里氏综合征(RS)主要有两种变体,即弥漫性大B细胞淋巴瘤(DLBCL)和霍奇金淋巴瘤(HL)变体。克隆关系定义为慢性淋巴细胞白血病(CLL)与RS克隆之间免疫球蛋白重链可变区(IGHV)序列相同,是预后不良患者的特征。由于方法的敏感性,这种分类在进行时未考虑小尺寸辅助克隆的可能性,这些辅助克隆与先前存在的主要CLL克隆具有相同的表型,但IGHV重排不同。在此,我们描述并从分子层面分析了一例特殊病例,该患者患有类似CLL的单克隆B细胞淋巴细胞增多症(MBL),随后依次发展为DLBCL(其发生与MBL进展为CLL同时出现)以及随后的HL。基于标准的IGHV克隆性分析,DLBCL被认为与同时期扩增的CLL克隆无克隆相关性,并作为淋巴瘤进行治疗,获得了持续缓解。三年后,该患者进一步发展为与之前克隆无关的HL,对苯达莫司汀耐药,成功接受了维布妥昔单抗和放疗治疗,随后又接受了帕博利珠单抗治疗。我们回顾性地进行了额外的分子检测,应用免疫球蛋白库(Ig-rep)技术的下一代测序(NGS)以及更灵敏的等位基因特异性寡核苷酸液滴数字PCR(ASO-ddPCR)策略,以定量研究疾病过程中收集的肿瘤标本中重排的IGHV基因的存在情况。在这个高度复杂的病例中,应用现代且灵敏的分子技术发现,最初被视为淋巴瘤的DLBCL实际上是先前存在的辅助B细胞克隆转化的结果,该克隆在首次诊断MBL时就已存在。类似的方法也应用于HL样本,显示其与先前的MBL和DLBCL无克隆相关性。